Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer [0.03%]
在EGFR突变型MET扩增肺癌中，获得性奥希替尼联合萨瓦利替尼抵抗由MET-D1228和MET-Y1230突变介导
Andrew J Piper-Vallillo,Brian T Halbert,Deepa Rangachari et al.
Andrew J Piper-Vallillo et al.
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations [0.03%]
2019冠状病毒病在肺癌患者中的感染情况：发病率、临床表现及鉴别诊断考虑因素
Andrew J Piper-Vallillo,Meghan J Mooradian,Catherine B Meador et al.
Andrew J Piper-Vallillo et al.
Introduction: Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incide...
Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital [0.03%]
新型冠状病毒疫情下肺癌患者：意大利大学医院的经验
Giorgio Scagliotti,Silvia Novello,Andrea Veltri et al.
Giorgio Scagliotti et al.
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China [0.03%]
新型冠状病毒肺炎疫情期间中国肺癌患者的实际情况
Rui Fu,Lin Wu,Chao Zhang et al.
Rui Fu et al.
Introduction: The coronavirus disease 2019 (COVID-19) outbreak throughout the world has affected millions of people in many ways, putting a huge burden on the health care system. The ongoing outbreak of this respiratory d...
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms [0.03%]
在EGFR突变的NSCLC患者中作为旁路耐药机制先后出现CCDC6-RET融合及BRAF V600E突变的个性化治疗
In this case report, we describe a case of sequential acquired CCDC6 -RET fusion and BRAF V600E mutation observed in a patient with EGFR-mutated NSCLC treated with osimertinib and with combined selpercatinib and osimertinib. The discovery o...